Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD

Respiration

Volumn 73, Issue 4, 2006, Pages 414-419

  Richter, Kai ^a,e   Stenglein, Stephan ^b   Mücke, Marion ^a   Sieder, Christian ^b   Schmidtmann, Sören ^c   Harnest, Ulf ^d   Weidinger, Gottfried ^b   Magnussen, Helgo ^a  

^a Pulmonary Research Institute   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c Pulmologische Praxis   (Germany)

^d Clinguard GmbH   (Germany)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Bronchodilation; Chronic obstructive pulmonary disease; Formoterol; Tiotropium

Indexed keywords

FORMOTEROL; FORMOTEROL FUMARATE; TIOTROPIUM BROMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; BRONCHODILATOR AGENTS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SAFETY; SCOPOLAMINE DERIVATIVES; SMOKING; TREATMENT OUTCOME;

EID: 33745182955     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091996     Document Type: Article

References (22)

1. Fabbri LM, Hurd SS; GOLD Scientific Committee: Global strategy for the diagnosis, management and prevention of COPD. Eur Respir J 2003;22:1-2.
2. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FP: Salmeterol versus formoterol in patients with moderately severe asthma; onset and duration of action. Eur Respir J 1996;9:1684-1688.
3. Richter K, Janicki S, Jörres RA, Magnussen H: Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002;19:865-871.
4. Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gors V, Kottakis J, Bourdeix I: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001;95:817-821.
5. Celik G, Kayacan O, Beder S, Durmaz G: Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999;66:434-439.
6. Friedman M, Della Cioppa G, Kottakis J: Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy 2002;22:1129-1139.
7. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG: Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur Respir J 1995;8:1506-1513.
8. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr: Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva®) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-1142.
9. Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 2000;118:1294-1302.
10. Beeh KM, Welte T, Buhl R: Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002;69:372-379.
11. Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub M, Barnes PJ: Effect of Ba 679 BR, a novel long-acting anticholinergic agent on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-1645.
12. Van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG: Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:639-644.
13. Maesen FPV, Smeete SJ, Costongs MAL, Zweers PGMA, Pfeil JP: Onset of action of formoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pract 1995;49:294-296.
14. Van Noord JA, Aumann J, Janssens E, Müller A, Cornelissen PJG: Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD. Am J Respir Crit Care Med 2003;167:A320.
15. Van Noord JA, Aumann J, Janssens E, Folgering H, Müller A, Cornelissen PJG: Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during two-week treatment periods. Am J Respir Crit Care Med 2003;167:A95.
16. Cazzola M, Di Marco FD, Santus P, Boveri B, Verga M, Matera MG, Centanni S: The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17:35-39.
17. ATS Statement: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
18. American Thoracic Society: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
19. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
20. Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758.
21. Beier J, Beeh KM, Troger K, Stenglein S, Bräutigam M, Buhl R, Schmidt EW: Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by body plethysmography. Pneumologie 2002;56:535-541.
22. Curtis JR, Deyo RA, Hudson LD: Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax 1994;49:162-170.